SCHEMBL17609571

SCHEMBL17609571

FC1(F)CCCCN1C1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.33
DPP4 P27487 1/20 0.30
DPP7 Q9UHL4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20390137 0.71 BDKRB2 (0.33) HSD11B1
SCHEMBL11568926 0.71 BDKRB2 (0.33) HSD11B1
SCHEMBL19987632 0.70 SIGMAR1 (0.34) HSD11B1
SCHEMBL29012979 0.68 PRCP (0.31)
SCHEMBL31343236 0.68 PRCP (0.31)
SCHEMBL29019534 0.67 PRCP (0.30)
SCHEMBL28815344 0.67 HSD11B1 (0.32) HSD11B1
SCHEMBL10858558 0.67 SIGMAR1 (0.32) HSD11B1
SCHEMBL29012929 0.66
SCHEMBL5492945 0.66 HSD11B1 (0.34) HSD11B1DPP4DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3746445-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY (US) 2020-12-09 EP claimed
CN-111655693-A Inhibition of transient receptor potential A1 ion channels 伊莱利利公司 2020-09-11 CN claimed
EP-3193880-B1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL LILLY CO ELI (US) 2020-03-25 EP claimed
WO-2019152465-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY (US) 2019-08-08 WO claimed
US-10221177-B2 Inhibiting the transient receptor potential A1 ion channel HYDRA BIOSCIENCES, INC. (US) 2019-03-05 US claimed
US-20170275285-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2017-09-28 US claimed
EP-3193880-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL Hydra Biosciences, Inc. (US) 2017-07-26 EP claimed
WO-2016044792-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL HYDRA BIOSCIENCES, INC. (US) 2016-03-24 WO claimed
EP-4233871-A2 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL Eli Lilly and Company (US) 2023-08-30 EP disclosed
CN-111655693-B Inhibition of transient receptor potential A1 ion channels 伊莱利利公司 2023-03-28 CN disclosed
US-11161849-B2 Inhibiting the transient receptor potential al ion channel ELI LILLY AND COMPANY (US) 2021-11-02 US disclosed
US-20200392136-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2020-12-17 US disclosed
EP-3746445-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY (US) 2020-12-09 EP disclosed
CN-111655693-A Inhibition of transient receptor potential A1 ion channels 伊莱利利公司 2020-09-11 CN disclosed
US-20190330212-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2019-10-31 US disclosed
WO-2019152465-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY (US) 2019-08-08 WO disclosed
US-10221177-B2 Inhibiting the transient receptor potential A1 ion channel HYDRA BIOSCIENCES, INC. (US) 2019-03-05 US disclosed
US-20170275285-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2017-09-28 US disclosed
EP-3193880-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL Hydra Biosciences, Inc. (US) 2017-07-26 EP disclosed
WO-2016044792-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL HYDRA BIOSCIENCES, INC. (US) 2016-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221177-B2 Inhibiting the transient receptor potential A1 ion channel TRPV1, TRPA1, TRPV2 HSD11B1 1988/4885DPP4 3069/4885DPP7 2440/4885
US-11161849-B2 Inhibiting the transient receptor potential al ion channel TRPV1, TRPA1, TRPV2 HSD11B1 2072/4885DPP4 3175/4885DPP7 2452/4885
US-20200392136-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL TRPV1, TRPA1, TRPV2 HSD11B1 1988/4885DPP4 3069/4885DPP7 2440/4885
US-20170275285-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL TRPV1, TRPA1, TRPV2 HSD11B1 1988/4885DPP4 3069/4885DPP7 2440/4885
US-20190330212-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL TRPV1, TRPA1, TRPV2 HSD11B1 1988/4885DPP4 3069/4885DPP7 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.